Abstract
One of the great challenges in dopaminergic structure-activity relationship studies is that the elements of the dopamine molecule can be incorporated within the matrix of a variety of ring systems, with retention of a high degree of potency and activity with respect to at least a portion of the spectrum of biological effects manifested by dopamine itself. Structures 1–6 illustrate some representative ring systems which have been studied.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cannon, J. G., Brubaker, A. N., Long, J. P., Flynn, J. R., Verimer, T., Harnirattisai, P., Costall, B., Naylor, R. J., and Nohria, V. (1981). 5,7-Dihydroxy-2-aminotetralin Derivatives: Synthesis and Assessment of Dopaminergic and Adrenergic Actions. J. Med. Chem., 24, 149–153.
Cannon, J. G., Hamer, R. L., Ilhan, M., Bhatnagar, R. K., and Long, J. P. (1984). Conformationally Restricted Congeners of Dopamine Derived from Octahydrobenzo[g]quinoline and Octahydrobenzo[f] quinoline. J. Med. Chem., 27, 190–195.
Cannon, J. G., Furlano, D. C., Koble, D. J., Koons, J. C., and Long, J. P. (1984). Possible Biologically Active Metabolites of 5-Hydroxy-6-methyl-2-di-n-propylaminotetralin. Life Sci., 34, 1679–1682.
Cannon, J. G. (1985). Dopamine Agonists. Prog. Drug Res., 29, 303–414.
Cannon, J. G., Amoo, V. E. D., Long, J. P., Bhatnagar, R. K., and Flynn, J. R. (1986). p-Dimethoxy-Substituted trans-Octahydrobenzo[f]- and [g]quinolines: Synthesis and Assessment of Dopaminergic Agonist Effects. J. Med. Chem., 29, 2529–2534.
Cannon, J. G. and Long, J. P. (1987). unpublished data.
Feenstra, M. G. P., Rollema, H., Mulder, T. B. A., and Horn, A. S. (1983). Amperometric Detection of Low Concentrations of Dopamine Receptor Agonists after Liquid Chromatographic On-Column Sample Enrichment: Effect of O-Methylation on Brain Concentrations of Dipropyl-5,6-ADTN and 6,7-ADTN. Life Sci., 32, 459–465.
Grol, C. J. and Rollema, H. (1977). Conformational Analysis of Dopamine by the INDO Molecular Orbital Method. J. Pharm. Pharmacol., 29, 153–156.
Hacksell, U., Arvidsson, L.-E., Svensson, U., Nilsson, J. L. G., Sanchez, D., Wikstrom, H., Lindberg, P., Hjorth, S., and Carlsson, A. (1981). 3-Phenylpiperidines. Central Dopamine Autoreceptor Stimulating Activity. J. Med. Chem., 24, 1475–1482.
Horn, A. S., Dijkstra, D., Feenstra, M. G. P., Grol, C. J., Rollema, H., and Westerink, B. H. C. (1980). Prodrugs of Some Dopaminergic 2-Aminotetralins: A Review of their Synthesis and Neurochemical Profiles. Eur. J. Med. Chem., 15, 387–392.
Horn, A. S., Dijkstra, D., Mulder, T. B. A., Rollema, H., and Westerink, B. H. C. (1981). Synthesis and Activity of a Metabolite of the Dopaminergic Agonist 6,7-ADTN. Eur. J. Med. Chem., 16, 469–472.
Liljefors, T. and Wikstrom, H. (1986). A Molecular Mechanics Approach to the Understanding of Presynaptic Selectivity for Centrally Acting Dopamine Receptor Agonists of the Phenylpiperidine Series. J. Med. Chem., 29, 1896–1904.
McDermed, J. D., Freeman, H. S., and Ferris, R. M. (1979). In Catecholamines: Basic and Clinical Frontiers, vol. 1. Enantioselectivity in the Binding of (+)- and (−)-2-Amino-6,7-dihydroxy-1,2,3,4-Tetrahydronaphthalene and Related Agonists to Dopamine Receptors, (eds. E. Usdin, I. J. Kopin, and J. Barchas) pp. 568–570. Pergamon Press, Elmsford, New York.
Rollema, H., Westerink, B. H. C., Mulder, T. B. A., Dijkstra, D., Feenstra, M. G. P., and Horn, A. S. (1980). The Significance of COMT Activity in Controlling Dopamine Agonist Levels in Brain and Serum: Studies with a Prodrug and a Metabolite of 6,7-ADTN. Eur. J. Pharmacol., 64, 313–323.
Rollema, H., Grol, C. J., and Feenstra, M. G. P. (1982). Metabolism of 2-Aminotetralins. Pharm. Weekbl. Sci. Ed., 4, 205–207.
Rollema, H. and Grol, C. J. (1983). Latentiated 2-Aminotetralins. Pharm. Weekbl. Sci. Ed., 5, 159–161.
Seiler, M. P. and Markstein, R. (1982). Further Characterization of Structural Requirements for Agonists at the Striatal Dopamine D-1 Receptor. Molec. Pharmacol., 22, 281–289.
Sindelar, R. D., Mott, J., Barfknecht, C. F., Arneric, S. P., Flynn, J. R., Long, J. P., and Bhatnagar, R. K. (1982). 2-Amino-4,7-dimethoxyindan Derivatives: Synthesis and Assessment of Dopaminergic and Cardiovascular Actions. J. Med. Chem., 25, 858–864.
Westerink, B. H. C., Dijkstra, D., Feenstra, M. G. P., Grol, C. J., Horn, A. S., Rollema, H., and Wirix, E. (1980). Dopaminergic Prodrugs: Brain Concentrations and Neurochemical Effects of 5,6- and 6,7-ADTN after Administration of a Dibenzoyl Ester. Eur. J. Pharmacol., 61, 7–15.
Youde, I. R., Raxworthy, M. J., Gulliver, P. A., Dijkstra, D., and Horn, A. S. (1984). The Metabolism of Dopamine, N,N-Dialkylated dopamines, and Derivatives of the Dopamine Agonist 2-amino-dihydroxy-l,2,3,4-Tetrahydronaphthalene (ADTN) by Catechol-0-Methyltransferase. J. Pharm. Pharmacol., 36, 309–313.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Copyright information
© 1988 Joseph G. Cannon
About this chapter
Cite this chapter
Cannon, J.G. (1988). The Status Quo and the Future. In: Beart, P.M., Woodruff, G.N., Jackson, D.M. (eds) Pharmacology and Functional Regulation of Dopaminergic Neurons. Satellite Symposia of the IUPHAR 10th International Congress of Pharmacology. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-10047-7_1
Download citation
DOI: https://doi.org/10.1007/978-1-349-10047-7_1
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-10049-1
Online ISBN: 978-1-349-10047-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)